NO175704C - Fremgangsmåte for fremstilling av et stabilt, farmasöytisk preparat av rekombinant interferon - Google Patents

Fremgangsmåte for fremstilling av et stabilt, farmasöytisk preparat av rekombinant interferon

Info

Publication number
NO175704C
NO175704C NO874445A NO874445A NO175704C NO 175704 C NO175704 C NO 175704C NO 874445 A NO874445 A NO 874445A NO 874445 A NO874445 A NO 874445A NO 175704 C NO175704 C NO 175704C
Authority
NO
Norway
Prior art keywords
preparation
stable pharmaceutical
recombinant interferon
ionic polymeric
biocompatible non
Prior art date
Application number
NO874445A
Other languages
English (en)
Other versions
NO874445L (no
NO175704B (no
NO874445D0 (no
Inventor
Ze Ev Shaked
Tracy Stewart
Jody Thomson
James William Thomson
Terrance Taford
Susan Hershenson
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of NO874445D0 publication Critical patent/NO874445D0/no
Publication of NO874445L publication Critical patent/NO874445L/no
Publication of NO175704B publication Critical patent/NO175704B/no
Publication of NO175704C publication Critical patent/NO175704C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO874445A 1986-10-27 1987-10-26 Fremgangsmåte for fremstilling av et stabilt, farmasöytisk preparat av rekombinant interferon NO175704C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92342386A 1986-10-27 1986-10-27

Publications (4)

Publication Number Publication Date
NO874445D0 NO874445D0 (no) 1987-10-26
NO874445L NO874445L (no) 1988-04-28
NO175704B NO175704B (no) 1994-08-15
NO175704C true NO175704C (no) 1994-11-23

Family

ID=25448670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO874445A NO175704C (no) 1986-10-27 1987-10-26 Fremgangsmåte for fremstilling av et stabilt, farmasöytisk preparat av rekombinant interferon

Country Status (9)

Country Link
EP (1) EP0270799B1 (no)
JP (1) JPS63179833A (no)
AT (1) ATE111744T1 (no)
AU (2) AU8019187A (no)
CA (1) CA1294215C (no)
DE (1) DE3750574T2 (no)
DK (1) DK563487A (no)
FI (1) FI95002C (no)
NO (1) NO175704C (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
IL89662A (en) * 1989-03-19 1997-11-20 Interpharm Lab Ltd Kiryat Weiz Pharmaceutical compositions comprising interferon-beta
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
WO1994009138A1 (en) * 1992-10-20 1994-04-28 Cetus Oncology Corporation Interleukin-6 receptor antagonists
AU709054B2 (en) 1994-03-07 1999-08-19 Chiron Corporation Compositions for the inhibition of TNF formation and uses thereof
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
GB9506051D0 (en) * 1995-03-24 1995-05-10 Univ Singapore Gene expression
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
CA2304808C (en) 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7544354B2 (en) 2000-10-27 2009-06-09 Novartis Vaccines And Diagnostics Methods of protein purification and recovery
CA2428144C (en) 2000-11-07 2012-01-10 Chiron Corporation Compositions of interferon-beta stabilized with highly purified mannitol
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
EP1446140A4 (en) 2001-10-15 2007-03-07 Novartis Vaccines & Diagnostic TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR)
DE602004028272D1 (de) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-monoklonalen antikörpern zur behandlung von multiplem myelom
EP2243491A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
ATE516819T1 (de) 2003-11-04 2011-08-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von b-zell-bedingtem krebs
JP4765039B2 (ja) 2003-11-04 2011-09-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃｄ４０抗原を発現する癌に対する治療方法。
SI1680141T1 (sl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
AU2011335551B2 (en) 2010-12-02 2016-10-06 Bionor Immuno As Peptide scaffold design
CA2821995C (en) 2011-01-06 2019-02-12 Bionor Immuno As Monomeric and multimeric peptides immunogenic against hiv
KR20150018870A (ko) 2012-06-06 2015-02-24 바이오노르 이뮤노 에이에스 면역원 및 투여 반응제로서 사용하기 위한 바이러스 단백질로부터 유래하는 펩타이드
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
CN105263390A (zh) 2013-04-23 2016-01-20 雪松-西奈医学中心 用于从荧光团同时录制可见光图像和红外光图像的系统和方法
CA2935404A1 (en) 2014-01-17 2015-07-23 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
US10029997B2 (en) 2014-06-12 2018-07-24 Cedars-Sinai Medical Center Compositions and methods for treating cancers
EP3173074A4 (en) 2014-07-22 2018-03-07 Lemonex Inc. Composition for delivering bioactive material or protein, and use thereof
EP3215186A4 (en) 2014-11-04 2018-10-24 University of Southern California COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
ES2842849T3 (es) 2015-05-05 2021-07-15 Univ California Péptidos CTL H3.3 y usos de los mismos
US11567078B2 (en) 2015-08-31 2023-01-31 Cedars-Sinai Medical Center Blood cell biomarker for late onset Alzheimer's disease
WO2017138924A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Compositions and methods for treating pancreatic cancer
KR20180103817A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
FI126979B (en) * 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof
WO2018143787A1 (ko) 2017-02-06 2018-08-09 주식회사 레모넥스 생리활성물질 전달체
KR20180091768A (ko) 2017-02-06 2018-08-16 주식회사 레모넥스 생리활성물질 전달체
US20210121493A1 (en) 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
KR102555433B1 (ko) * 2018-04-19 2023-07-13 에르테에스 로만 테라피-시스테메 아게 인터페론 적용을 위한 마이크로니들 시스템
US11690799B2 (en) 2018-04-19 2023-07-04 Lts Lohmann Therapie-Systeme Ag Microneedle system for applying interferon
US20210395358A1 (en) 2018-11-08 2021-12-23 Cedars-Sinai Medical Center Use of clazakizumab to desensitize and improve renal transplantation in hla-sensitized patients
JP2022514381A (ja) 2018-12-20 2022-02-10 セダーズ－シナイ メディカル センター 臓器移植の慢性抗体介在性拒絶反応の処置でのクラザキズマブ
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55102519A (en) * 1979-01-31 1980-08-05 Green Cross Corp:The Stabilization of interferon
CA1190148A (en) * 1981-10-13 1985-07-09 Samuel S. Asculai Interferon-containing compositions
JPS5910524A (ja) * 1982-07-08 1984-01-20 Toray Ind Inc インタ−フエロン組成物およびその製造法
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
DE3381553D1 (de) * 1982-10-25 1990-06-21 Genentech Inc Synergistische humaninterferonaktivitaet.
EP0150067A3 (en) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物

Also Published As

Publication number Publication date
FI95002C (fi) 1995-12-11
ATE111744T1 (de) 1994-10-15
AU659127B2 (en) 1995-05-11
NO874445L (no) 1988-04-28
DE3750574D1 (de) 1994-10-27
CA1294215C (en) 1992-01-14
AU1063392A (en) 1992-03-19
FI95002B (fi) 1995-08-31
FI874706A0 (fi) 1987-10-26
NO175704B (no) 1994-08-15
EP0270799B1 (en) 1994-09-21
DE3750574T2 (de) 1995-02-02
DK563487A (da) 1988-04-28
NO874445D0 (no) 1987-10-26
EP0270799A1 (en) 1988-06-15
DK563487D0 (da) 1987-10-27
JPS63179833A (ja) 1988-07-23
AU8019187A (en) 1988-04-28
FI874706A (fi) 1988-04-28

Similar Documents

Publication Publication Date Title
NO175704C (no) Fremgangsmåte for fremstilling av et stabilt, farmasöytisk preparat av rekombinant interferon
ATE74512T1 (de) Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
NO179479C (no) Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
NO883926D0 (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
KR950703999A (ko) 변성된 인슐린-유사 성장인자(modified insulin-like growth factors)
DK0388220T3 (da) Præparater til vedvarende frigivelse af klorhexidin
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
BG91270A (bg) Антивирусно и антибактериално средство и метод за използването му
ATE106247T1 (de) Formulierung für rekombinantes beta-interferon, verfahren zur gewinnung und stabilisierung des beta-interferons und dessen verwendung.
SE8402560L (sv) Farmaceutisk komposition
DK0759775T3 (da) Flydende IFN-beta-formuleringer
DE3854290D1 (de) Stabilisierung von therapeutisch wirksamen Proteinen in pharmazeutischen Zubereitungen.
DE59107240D1 (de) Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
FR2684878B1 (fr) Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
NO301805B1 (no) Fremgangsmåte for fremstilling av et stabilt, galenisk, vandig preparat av erytropoietin
IT8522442A0 (it) Derivati nucleosidici aventi proprieta' antierpetiche, composizioni farmaceutiche che licontengono e procedimento per lapreparazione degli ingredienti attivi.

Legal Events

Date Code Title Description
MK1K Patent expired